BofA Securities Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Maintains Target Price $50

Futu News00:31 · Ratings

Morgan Stanley Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Maintains Target Price $56

Futu News00:31 · Ratings

Strategic Focus and Financial Resilience: Terence Flynn's Positive Outlook on Intellia Therapeutics

TipRanksJan 11 23:36

Analysts' Top Healthcare Picks: Inozyme Pharma (INZY), Intellia Therapeutics (NTLA)

TipRanksJan 11 23:30 · Ratings

Intellia Therapeutics Price Target Lowered to $50 From $70 at BMO Capital

Yahoo FinanceJan 11 23:20

Intellia Therapeutics Price Target Lowered to $60 From $70 at Wells Fargo

Yahoo FinanceJan 11 20:36